StreetInsider.com News Articles

Roth/MKM Starts Abeona Therapeutics (ABEO) at Buy

Thu, 17 Sep 2026 02:52:29 -0400

Roth/MKM analyst Boobalan Pachaiyappan initiates coverage on Abeona Therapeutics (NASDAQ: ABEO) with a Buy rating and a price target of $17.00.

The analyst comments: “We initiate coverage of ABEO with a Buy rating and 12-month PT of $17. Our bullish view is predicated upon ZEVASKYN’s durable profile targeting Recessive Dystrophic Epidermolysis Bullosa (RDEB)—a rare skin disease. Despite carrying a $3.1M price tag, ZEVASKYN has drawn no payor denials to date and is being implemented at 8/10 Qualified Treatment Center (QTC) U.S. sites. Our models estimate ABEO achieves GAAP net income profitability in 1Q27 and >$275M in sales in 2029. Should an

Roth/MKM Starts Abeona Therapeutics (ABEO) at Buy

Thu, 17 Sep 2026 02:52:29 -0400

Roth/MKM analyst Boobalan Pachaiyappan initiates coverage on Abeona Therapeutics (NASDAQ: ABEO) with a Buy rating and a price target of $17.00.

Abeona adds UF Health as 8th treatment center for Zevaskyn

Wed, 16 Sep 2026 07:31:19 -0400

Abeona Therapeutics (Nasdaq: ABEO) announced that University of Florida Health in Gainesville, Florida, has been activated as the eighth Qualified Treatment Center for administering Zevaskyn (prademagene zamikeracel), a gene-modified cellular sheet therapy for recessive dystrophic epidermolysis bullosa (RDEB).

UF Health is described in the company's statement as the only treatment center for Zevaskyn in the Southeastern United States. The facility has begun patient identification and onboarding activities.

Zevaskyn is an autologous cell sheet-based gene therapy indicated for the treatment of wounds in adult and pediatric patients with RDEB, a rare genetic skin disorder in which patients cannot produce functional type VII collagen,

Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®

Wed, 16 Sep 2026 07:30:00 -0400

CLEVELAND, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet need, today announced the activation of University of Florida Health (UF Health) in Gainesville, Florida, as the eighth Qualified Treatment Center (QTC) for the administration of ZEVASKYN (prademagene zamikeracel) gene-modified cellular sheets. ZEVASKYN is the first and only autologous gene-modified cellular sheets for the treatment of wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB).

“Activation of UF Health as a QTC represents an important step in expanding access to

Abeona Therapeutics® Announces Activation of University of Florida Health as Newest Qualified Treatment Center for ZEVASKYN®

Wed, 16 Sep 2026 07:30:00 -0400

“Activation of UF Health as a QTC represents an important step in expanding access to

Form 8-K ABEONA THERAPEUTICS INC. For: Sep 15

Tue, 15 Sep 2026 12:00:00 -0400

si-local-file:///var/storage/secattach/20260915/27063667.html

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

Wed, 02 Sep 2026 07:30:00 -0400

CLEVELAND, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in September 2026:

Cantor Global Healthcare Conference 2026: Fireside chat on Wednesday, September 9, 2026, at 8:00 a.m. ET and investor meetings.
H.C. Wainwright 28th Annual Global Investment Conference: Company presentation on Tuesday, September 15, 2026, at 12:00 p.m. ET and investor meetings.
Morgan Stanley 24th Annual Global Healthcare Conference: Fireside chat on Wednesday, September 16, 2026, at

Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences

Wed, 02 Sep 2026 07:30:00 -0400

Cantor Global Healthcare Conference 2026: Fireside chat on Wednesday, September 9, 2026, at 8:00 a.m. ET and investor meetings.
H.C. Wainwright 28th Annual Global Investment Conference: Company presentation on Tuesday, September 15, 2026, at 12:00 p.m. ET and investor meetings.
Morgan Stanley 24th Annual Global Healthcare Conference: Fireside chat on Wednesday, September 16, 2026, at

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 01 Sep 2026 07:30:00 -0400

CLEVELAND, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

On August 31, 2026, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to five individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 13,300 restricted shares of Abeona common stock. One-third of the shares subject to such restricted stock awards

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 01 Sep 2026 07:30:00 -0400

Form SCHEDULE 13G/A ABEONA THERAPEUTICS INC. Filed by: MONTANOVA CAPITAL, LLC

Fri, 14 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260814/26931426.html

Form SCHEDULE 13G/A ABEONA THERAPEUTICS INC. Filed by: MONTANOVA CAPITAL, LLC

Fri, 14 Aug 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260814/26931426.html

Abeona Therapeutics (ABEO) PT Lowered to $21 at Oppenheimer

Fri, 14 Aug 2026 08:33:33 -0400

Oppenheimer analyst Jeff Jones lowered the price target on Abeona Therapeutics (NASDAQ: ABEO) to $21.00 (from $22.00) while maintaining a Outperform rating.

Form 10-Q ABEONA THERAPEUTICS INC. For: Jun 30

Thu, 13 Aug 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20260813/26916508.html

Form 10-Q ABEONA THERAPEUTICS INC. For: Jun 30

Thu, 13 Aug 2026 07:31:00 -0400

si-local-file:///var/storage/secattach/20260813/26916508.html

Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update

Thu, 13 Aug 2026 07:30:00 -0400

- Q2 net ZEVASKYN® revenue increased 31% quarter-over-quarter to $11.4 million –

- Five patients treated with ZEVASKYN in Q2 2026 and three treatments in Q3 2026 to-date; since launch, 12 treatments completed –

- Expanding QTC network now includes seven sites nationwide; growing number of QTCs progressing patients through treatment process –

- $146.8 million in cash, cash equivalents and short-term investments as of June 30, 2026 –

CLEVELAND, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the second quarter

Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update

Thu, 13 Aug 2026 07:30:00 -0400

- Q2 net ZEVASKYN® revenue increased 31% quarter-over-quarter to $11.4 million –

- Five patients treated with ZEVASKYN in Q2 2026 and three treatments in Q3 2026 to-date; since launch, 12 treatments completed –

- Expanding QTC network now includes seven sites nationwide; growing number of QTCs progressing patients through treatment process –

- $146.8 million in cash, cash equivalents and short-term investments as of June 30, 2026 –

CLEVELAND, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the second quarter

Form 8-K ABEONA THERAPEUTICS INC. For: Aug 13

Thu, 13 Aug 2026 07:30:00 -0400

si-local-file:///var/storage/secattach/20260813/26916494.html

Form 8-K ABEONA THERAPEUTICS INC. For: Aug 13

Thu, 13 Aug 2026 07:30:00 -0400

si-local-file:///var/storage/secattach/20260813/26916494.html

Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026

Thu, 06 Aug 2026 07:30:00 -0400

CLEVELAND, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that the Company will host a conference call on Thursday, August 13, 2026 at 8:30 a.m. ET to discuss its financial results for the second quarter of 2026 and provide a corporate update. Abeona will announce its financial results for this period in a press release to be issued prior to the call.

To access the live conference call, please dial 888-506-0062 (U.S. toll-free) or 973-528-0011 (international) and enter Entry Code: 245916 approximately five minutes prior to the start of the

Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026

Thu, 06 Aug 2026 07:30:00 -0400

To access the live conference call, please dial 888-506-0062 (U.S. toll-free) or 973-528-0011 (international) and enter Entry Code: 245916 approximately five minutes prior to the start of the

CMS grants NTAP status for Abeona's ZEVASKYN skin therapy

Tue, 04 Aug 2026 07:31:18 -0400

Abeona Therapeutics Inc. (Nasdaq: ABEO) announced that the Centers for Medicare & Medicaid Services (CMS) has granted New Technology Add-On Payment (NTAP) status for ZEVASKYN (prademagene zamikeracel) under the Fiscal Year 2027 Hospital Inpatient Prospective Payment System Final Rule.

NTAP status provides supplemental CMS reimbursement above standard hospital payments for technologies that meet CMS criteria, including demonstrating substantial clinical improvement over existing alternatives.

ZEVASKYN is indicated for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB), a severe genetic skin disease that causes fragile skin and wounds that are difficult to heal. The therapy incorporates a

CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN®

Tue, 04 Aug 2026 07:30:00 -0400

NTAP Designation Expected to Support Medicare Patient Access, Treatment Center Economics and Commercial Adoption

CLEVELAND, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted New Technology Add-On Payment (NTAP) status for ZEVASKYN (prademagene zamikeracel) under the Fiscal Year 2027 Hospital Inpatient Prospective Payment System (IPPS) Final Rule.

NTAP status provides supplemental CMS reimbursement above standard hospital payments to support access to innovative therapies like ZEVASKYN. This additional funding is

CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN®

Tue, 04 Aug 2026 07:30:00 -0400

NTAP Designation Expected to Support Medicare Patient Access, Treatment Center Economics and Commercial Adoption

NTAP status provides supplemental CMS reimbursement above standard hospital payments to support access to innovative therapies like ZEVASKYN. This additional funding is

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 03 Aug 2026 07:30:00 -0400

CLEVELAND, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

On July 31, 2026, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to two individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 10,800 restricted shares of Abeona common stock. One-third of the shares subject to such restricted stock awards